Novel Expert Perspectives in Treating Moderate-to-Severe Ulcerative Colitis

Expert gastroenterologists examine the sequencing of therapies and optimizing treatment selection in the evolving treatment landscape for ulcerative colitis.

EP. 1: Overview of Inflammatory Bowel Disease (IBD)

May 31st 2022

David P. Hudesman, MD, and Marla Dubinsky, MD, define symptoms and potential disease triggers for inflammatory bowel disease (IBD).

EP. 2: Disease Subtypes and Differential Diagnosis of UC and CD

May 31st 2022

Ellen J. Scherl, MD, highlights the different subtypes of ulcerative colitis and the differential diagnosis with Crohn’s disease.

EP. 3: Impact of IBD on Quality of Life

June 7th 2022

Drs David P. Hudesman, Marla Dubinsky, and Ellen J. Scherl explore the impact of IBD and ulcerative colitis on a patient’s quality of life.

EP. 4: Approaching Ulcerative Colitis Treatment Selection

June 7th 2022

Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.

EP. 5: Using 5-ASAs and Steroids for UC Treatment

June 14th 2022

Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.

EP. 6: UC Treatment: Anti-integrin Antibodies and Anti-interleukins

June 14th 2022

David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.

EP. 7: Role of JAK Inhibitors and S1P Receptor Modulators for UC Treatment

June 21st 2022

Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.

EP. 8: Switching Therapies in Ulcerative Colitis

June 21st 2022

David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.